Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis - Divided Values

Type II network, divided values. Interestingly most of the proteins in the first 100 positions in this table would occur in the divided ranks table between position 100 and 200, indicating a difference in emphasis between the two simulations but not in the overall function. The fully annotated table, include Ensembl gene identifiers and network values can be found in the supplementary data.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 151 to 200 of 3228 in total 
Value Type: Measured
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.16666666666667\textwidth}
\def\wcB{0.16666666666667\textwidth}
\def\wcC{0.16666666666667\textwidth}
\def\wcD{0.16666666666667\textwidth}
\def\wcE{0.16666666666667\textwidth}
\begin{longtable}{|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
151\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
sh2 domain containing 3c; novel sh2-containing protein 3; sh2 domain-containing 3c; likely ortholog of mouse cas/hef1-associated signal transducer. [source:refseq;acc:nm\_005489]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4578.09\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5939.91\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.29746\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
152\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma antigen, family d, 4 isoform 1; mage1 protein; mage-e1 protein; maged4 protein. [source:refseq;acc:nm\_030801]\vspace{3pt}}&\multirow{21}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
23693.7\vspace{3pt}}}&\multirow{21}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
18263\vspace{3pt}}}&\multirow{21}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.29736\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
153\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
hepatocellular carcinoma-associated protein hca3. [source:refseq;acc:nm\_138703]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
154\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 3 (mage-3 antigen) (antigen mz2-d). [source:swissprot;acc:p43357]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
155\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 11 (mage-11 antigen). [source:swissprot;acc:p43364]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
156\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 2 (mage-2 antigen). [source:swissprot;acc:p43356]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
157\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
hepatocellular carcinoma-associated protein hca1. [source:refseq;acc:nm\_020932]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
158\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 6 (mage-6 antigen) (mage3b). [source:swissprot;acc:p43360]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
159\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
necdin. [source:swissprot;acc:q99608]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
160\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen d1 (mage-d1 antigen) (neurotrophin receptor-interacting mage homolog) (pro2292). [source:swissprot;acc:q9y5v3]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
161\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen f1 (mage-f1 antigen). [source:swissprot;acc:q9hay2]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
162\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma antigen, family b, 6. [source:refseq;acc:nm\_173523]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
163\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 4 (mage-4 antigen) (mage-x2) (mage-41). [source:swissprot;acc:p43358]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
164\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 9 (mage-9 antigen). [source:swissprot;acc:p43362]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
165\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 8 (mage-8 antigen). [source:swissprot;acc:p43361]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
166\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen c1 (mage-c1 antigen) (cancer-testis antigen ct7). [source:swissprot;acc:o60732]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
167\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 12 (mage-12 antigen) (mage12f). [source:swissprot;acc:p43365]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
168\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 1 (mage-1 antigen) (antigen mz2-e). [source:swissprot;acc:p43355]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
169\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen 10 (mage-10 antigen). [source:swissprot;acc:p43363]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
170\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen b1 (mage-b1 antigen) (mage-xp antigen) (dss-ahc critical interval mage superfamily 10) (dam10). [source:swissprot;acc:p43366]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
171\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
melanoma-associated antigen d2 (mage-d2 antigen) (breast cancer associated gene 1 protein) (bcg-1) (11b6) (hepatocellular carcinoma associated protein jcl-1). [source:swissprot;acc:q9unf1]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
172\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
trophinin. [source:swissprot;acc:q12816]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
173\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
breast cancer antiestrogen resistance 3. [source:refseq;acc:nm\_003567]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4579.34\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5940.64\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.29727\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
174\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
mad protein (max dimerizer). [source:swissprot;acc:q05195]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4455.95\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5774.03\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.2958\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
175\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
max interacting protein 1 (mxi1 protein). [source:swissprot;acc:p50539]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4456.67\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5773.77\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.29553\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
176\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
max-interacting transcriptional repressor mad4 (max-associated protein 4) (max dimerization protein 4). [source:swissprot;acc:q14582]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4456.93\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5773.67\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.29544\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
177\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
max dimerization protein 3; likely ortholog of mouse max dimerization protein 3. [source:refseq;acc:nm\_031300]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4457.06\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5773.63\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.29539\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
178\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
myosin vb (myosin 5b) (fragment). [source:swissprot;acc:q9ulv0]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
21591.5\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
27904.5\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.29238\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
179\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
myosin vc (myosin 5c). [source:swissprot;acc:q9nqx4]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
180\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
myosin va (myosin 5a) (dilute myosin heavy chain, non-muscle) (myosin heavy chain 12) (myoxin). [source:swissprot;acc:q9y4i1]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
181\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
eukaryotic translation initiation factor 4 gamma, 3. [source:refseq;acc:nm\_003760]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4068.56\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5252.6\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.29102\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
182\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
rna-binding protein. [source:refseq;acc:nm\_019027]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
4069.83\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
5252.17\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.29051\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
183\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
apobec-1 complementation factor isoform 1; apobec-1 stimulating protein; apo-b rna editing protein. [source:refseq;acc:nm\_014576]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
184\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ns1-associated protein 1. [source:refseq;acc:nm\_006372]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
185\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
heterogeneous nuclear ribonucleoprotein r (hnrnp r). [source:swissprot;acc:o43390]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
186\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
eukaryotic translation initiation factor 4 gamma (eif-4-gamma) (eif- 4g) (eif4g) (p220). [source:swissprot;acc:q04637]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4071.1\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5251.75\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.29001\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
187\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
small nuclear ribonucleoprotein sm d3 (snrnp core protein d3) (sm-d3). [source:swissprot;acc:p43331]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4569.48\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5885.79\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.28807\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
188\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
source of immunodominant mhc-associated peptides; homolog of yeast stt3 gene. [source:refseq;acc:nm\_178862]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
4571.89\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
5864.86\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.28281\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
189\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
oligosaccharyl transferase stt3 subunit homolog (b5) (integral membrane protein 1) (tmc). [source:swissprot;acc:p46977]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
190\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kda subunit precursor (ec 2.4.1.119) (oligosaccharyl transferase 48 kda subunit) (ddost 48 kda subunit). [source:swissprot;acc:p39656]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
191\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
splicing factor 3b subunit 1 (spliceosome associated protein 155) (sap 155) (sf3b155) (pre-mrna splicing factor sf3b 155 kda subunit). [source:swissprot;acc:o75533]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4638.1\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5923.4\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.27712\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
192\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
a-raf proto-oncogene serine/threonine-protein kinase (ec 2.7.1.-) (a-raf-1) (proto-oncogene pks). [source:swissprot;acc:p10398]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
17757.5\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
14008\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.26767\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
193\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
raf proto-oncogene serine/threonine-protein kinase (ec 2.7.1.-) (raf-1) (c-raf). [source:swissprot;acc:p04049]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
17756.5\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
14007.3\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.26766\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
194\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
cyclin g2. [source:swissprot;acc:q16589]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
17738.6\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
13995.7\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.26743\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
195\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
cyclin g1 (cyclin g). [source:swissprot;acc:p51959]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
17738.5\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
13995.6\vspace{3pt}}&\\\cline{1-2}\cline{4-5}
\parbox{\wcA}{\vspace{3pt}\noindent
196\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 56 kda regulatory subunit, epsilon isoform (pp2a, b subunit, b' epsilon isoform) (pp2a, b subunit, b56 epsilon isoform) (pp2a, b subunit, pr61 epsilon isoform) (pp2a, b subunit, r5 epsilon isoform). [source:swissprot;acc:q16537]\vspace{3pt}}&&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
13995.7\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.26742\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
197\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 56 kda regulatory subunit, alpha isoform (pp2a, b subunit, b' alpha isoform) (pp2a, b subunit, b56 alpha isoform) (pp2a, b subunit, pr61 alpha isoform) (pp2a, b subunit, r5 alpha isoform). [source:swissprot;acc:q15172]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
198\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
b-raf proto-oncogene serine/threonine-protein kinase (ec 2.7.1.-) (p94) (v-raf murine sarcoma viral oncogene homolog b1). [source:swissprot;acc:p15056]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
17710.9\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
13977.7\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.26708\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
199\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, catalytic subunit, alpha isoform (ec 3.1.3.16) (pp2a-alpha) (replication protein c) (rp-c). [source:swissprot;acc:p05323]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4916.8\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3888.18\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.26455\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
200\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
crk-associated substrate (p130cas) (breast cancer anti-estrogen resistance 1 protein). [source:swissprot;acc:p56945]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4808.79\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6074.21\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.26315\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/